China Biologic Products (CBPO) Reports Q1 EPS of $0.94
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- S&P 500, Nasdaq ease from record highs as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Caribou Biosciences to halt CAR-T programs, explore sale
- Sportradar to sell Synergy Sports coaching unit for $170M
- Emera and Canadian Utilities agree to merge in $72B all-share deal
China Biologic Reports Financial Results for the First Quarter of 2016
May 4, 2016 5:00 PM EDTBEIJING, May 4, 2016 /PRNewswire/ --Â China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the first quarter of 2016.
First Quarter 2016 Financial Highlights
Total sales in the first quarter of 2016 increased by 29.4% in RMB terms, or 21.6% in USD terms, to $85.6 million from $70.4 million in the same quarter of 2015. Gross profit increased by 12.2% to $51.5 million from $45.9 million in the same quarter of 2015. Gross margin decreased to 60.2% in the... More


